LeMaitre Vascular’s (LMAT) “Buy” Rating Reaffirmed at Roth Capital

Roth Capital reiterated their buy rating on shares of LeMaitre Vascular (NASDAQ:LMAT) in a research note released on Wednesday,Benzinga reports. They currently have a $108.00 target price on the medical instruments supplier’s stock.

LMAT has been the topic of several other research reports. Barrington Research reaffirmed an “outperform” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of LeMaitre Vascular in a research report on Wednesday, October 8th. Finally, Cantor Fitzgerald increased their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $100.60.

LeMaitre Vascular Price Performance

Shares of LMAT opened at $86.27 on Wednesday. The company has a 50 day moving average price of $89.94 and a 200-day moving average price of $87.01. LeMaitre Vascular has a fifty-two week low of $71.42 and a fifty-two week high of $109.58. The stock has a market capitalization of $1.95 billion, a PE ratio of 41.88, a PEG ratio of 2.29 and a beta of 0.77. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.03. The company had revenue of $63.15 million for the quarter, compared to analyst estimates of $62.48 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. LeMaitre Vascular’s revenue was up 15.0% compared to the same quarter last year. During the same period last year, the company posted $0.52 earnings per share. Equities analysts predict that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Bridget A. Ross sold 2,500 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $94.00, for a total value of $235,000.00. Following the completion of the transaction, the director owned 2,916 shares in the company, valued at $274,104. This trade represents a 46.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director John A. Roush sold 6,561 shares of the firm’s stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.55, for a total value of $607,220.55. Following the completion of the transaction, the director owned 2,916 shares of the company’s stock, valued at $269,875.80. This trade represents a 69.23% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 20,815 shares of company stock worth $1,929,206. Insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust raised its stake in LeMaitre Vascular by 1,913.3% in the 2nd quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 287 shares during the last quarter. Cornerstone Planning Group LLC raised its stake in LeMaitre Vascular by 534.0% in the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 283 shares during the last quarter. First Horizon Corp purchased a new position in LeMaitre Vascular in the 3rd quarter worth $39,000. Geneos Wealth Management Inc. raised its stake in LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 398 shares during the last quarter. Finally, EverSource Wealth Advisors LLC purchased a new position in LeMaitre Vascular in the 2nd quarter worth $47,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.